The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Apremilast Promising for Plaque Psoriasis

Apremilast Promising for Plaque Psoriasis

July 6, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The recent phase 3, multicenter, ADVANCE trial investigated the efficacy of apremilast (Otezla), an oral phosphodiesterase 4 (PDE4) inhibitor, in adults with mild to moderate plaque psoriasis.1 The treatment is currently approved by the U.S. Food & Drug Administration (FDA) to treat adults with active psoriatic arthritis, adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and adults with oral ulcers associated with Behçet’s disease.2

You Might Also Like
  • Mirikizumab Promising for Plaque Psoriasis
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
Explore This Issue
August 2020
Also By This Author
  • FDA Approves Baricitinib for RA Patients

The ADVANCE trial was randomized, placebo controlled and double blind. At week 16, the study’s primary endpoint, patients treated with 30 mg of apremilast twice daily had statistically significant improvements in the static Physician’s Global Assessment (sPGA) response compared with placebo-treated patients. (Note: Statistically significant improvement was defined as an sPGA score of clear [0] or almost clear [1], with at least a two-point reduction from baseline.)

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Additionally at week 16, apremilast-treated patients showed statistically significant improvements, compared with placebo-treated patients, in multiple secondary endpoints. These secondary endpoints included at least a 75% improvement from baseline in the percent of affected body surface area (BSA), a change in total BSA score from baseline, and a change in Psoriasis Area and Severity Index total score from baseline.

The most common adverse events, which occurred in at least 5% of patients, were diarrhea, headache, nausea, nasopharyngitis and upper respiratory tract infection. The adverse events observed were consistent with the known safety profile of apremilast. Amgen, the treatment’s maker, plans to submit these data to the FDA for inclusion in apremilast’s prescribing information.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Amgen Inc. News release: Amgen announces positive top-line results from Otezla (apremilast) phase 3 ADVANCE study in mild to moderate plaque psoriasis. 2020 May 6.
  2. U.S. Food and Drug Administration. Prescribing information: Otezla. 2020 Apr 10.

Filed Under: Analgesics, Drug Updates Tagged With: apremilast, plaque psoriasis, skinIssue: August 2020

You Might Also Like:
  • Mirikizumab Promising for Plaque Psoriasis
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.